Director at Providence St Joseph Health
- Key developments in the broader heart failure market and HFrEF (heart failure with reduced ejection fraction) – patient population, unmet need and challenges
- Cytokinetics (NASDAQ: CYTK) vs Bristol-Myers Squibb (NYSE: BMY) – omecamtiv mecarbil vs danicamtiv and aficamten vs mavacamten MoA (mechanism of action) for HCM (hypertrophic cardiomyopathy)
- Potential challenges for omecamtiv mecarbil's FDA approval
- 2022 outlook across Cytokinetics’ assets and broader treatment market
Could you outline the heart failure market, highlighting the standard of care, unmet need and any other impactful factors?
Is there anything else to highlight about therapies and treatments for heart failure?
What’s your assessment of Cytokinetics’ omecamtiv mecarbil for treating heart failure, including the mechanism of action and what makes it unique?
How does omecamtiv compare with danicamtiv, a cardiac myosin activator from BMS [Bristol-Myers Squibb] and MyoKardia?
What benchmarks should we use to interpret success or failure when assessing new data from the GALACTIC-HF and METEORIC-HF trials? What should we be aware of?
Do you remain hopeful that omecamtiv mecarbil will gain FDA approval? What percentage of the patient population would benefit from this drug or receive it, given potential challenges with market adoption?
Is there anything else to note about omecamtiv mecarbil?
What do you make of Cytokinetics’ aficamten for HCM [hypertrophic cardiomyopathy]? What are some of this candidate’s main challenges or advantages vs BMS’s mavacamten and other competition?
Aficamten has gained breakthrough designation for obstructive HCM based on the REDWOOD-HCM phase 2 trial results. What was most or least impressive to you about the results and what should we continue to monitor?
Is there anything else to highlight about Cytokinetics’ assets or the broader space?
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited